DrugPatentWatch Database Preview

Patents Expiring in October 2031

« Back to Dashboard

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use
Sanofi-aventis Us	ADLYXIN	lixisenatide	SOLUTION;SUBCUTANEOUS	208471-002	Jul 27, 2016		RX	Yes	Yes			Y
Sanofi-aventis Us	ADLYXIN	lixisenatide	SOLUTION;SUBCUTANEOUS	208471-001	Jul 27, 2016		RX	Yes	Yes			Y
Mannkind	AFREZZA	insulin recombinant human	POWDER;INHALATION	022472-003	Apr 17, 2015		RX	Yes	No						METHOD OF CONTROLLING GLYCEMIA IN DIABETICS BY ADMINISTERING AN INITIAL DOSE OF INSULIN-FDKP WITH A MEAL; DETERMINING BLOOD GLUCOSE LEVEL 1-2 HRS AFTER AND ADMINISTERING A SUPPLEMENTAL DOSE OF INSULIN-FDKP IF POSTPRANDIAL GLUCOSE LEVEL IS >140 MG/DL
Mannkind	AFREZZA	insulin recombinant human	POWDER;INHALATION	022472-002	Jun 27, 2014		RX	Yes	Yes						METHOD OF CONTROLLING GLYCEMIA IN DIABETICS BY ADMINISTERING AN INITIAL DOSE OF INSULIN-FDKP WITH A MEAL; DETERMINING BLOOD GLUCOSE LEVEL 1-2 HRS AFTER AND ADMINISTERING A SUPPLEMENTAL DOSE OF INSULIN-FDKP IF POSTPRANDIAL GLUCOSE LEVEL IS >140 MG/DL